These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 25058459)

  • 1. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
    Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
    Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4.
    Rademakers SE; Lok J; van der Kogel AJ; Bussink J; Kaanders JH
    BMC Cancer; 2011 May; 11():167. PubMed ID: 21569415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of metabolism-related proteins in phyllodes tumors.
    Kwon JE; Jung WH; Koo JS
    Tumour Biol; 2013 Feb; 34(1):115-24. PubMed ID: 22986897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer.
    Yan P; Li YH; Tang ZJ; Shu X; Liu X
    Asian Pac J Cancer Prev; 2014; 15(20):8923-9. PubMed ID: 25374230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
    Pinheiro C; Sousa B; Albergaria A; Paredes J; Dufloth R; Vieira D; Schmitt F; Baltazar F
    Histol Histopathol; 2011 Oct; 26(10):1279-86. PubMed ID: 21870331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
    Mboge MY; Chen Z; Khokhar D; Wolff A; Ai L; Heldermon CD; Bozdag M; Carta F; Supuran CT; Brown KD; McKenna R; Frost CJ; Frost SC
    Biochem J; 2019 May; 476(10):1497-1513. PubMed ID: 31072911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.
    Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J
    J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry.
    Choi J; Jung WH; Koo JS
    Pathobiology; 2013; 80(1):41-52. PubMed ID: 22832328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.
    Witkiewicz AK; Whitaker-Menezes D; Dasgupta A; Philp NJ; Lin Z; Gandara R; Sneddon S; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Cell Cycle; 2012 Mar; 11(6):1108-17. PubMed ID: 22313602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverging prognostic impacts of hypoxic markers according to NSCLC histology.
    Andersen S; Eilertsen M; Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
    Lung Cancer; 2011 Jun; 72(3):294-302. PubMed ID: 21075472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4.
    Meijer TW; Schuurbiers OC; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; Verhagen AF; Lok J; van der Heijden HF; Rademakers SE; Span PN; Bussink J
    Lung Cancer; 2012 Jun; 76(3):316-23. PubMed ID: 22153830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
    BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Ong CHC; Lee DY; Lee B; Li H; Lim JCT; Lim JX; Yeong JPS; Lau HY; Thike AA; Tan PH; Iqbal J
    Breast Cancer Res; 2022 Jun; 24(1):38. PubMed ID: 35659359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation.
    Sáenz-de-Santa-María I; Bernardo-Castiñeira C; Secades P; Bernaldo-de-Quirós S; Rodrigo JP; Astudillo A; Chiara MD
    Oncotarget; 2017 Feb; 8(8):13730-13746. PubMed ID: 28099149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure.
    Andersen S; Solstad Ø; Moi L; Donnem T; Eilertsen M; Nordby Y; Ness N; Richardsen E; Busund LT; Bremnes RM
    Urol Oncol; 2015 Aug; 33(8):338.e9-17. PubMed ID: 26066969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
    Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
    Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes.
    Vaz CV; Marques R; Alves MG; Oliveira PF; Cavaco JE; Maia CJ; Socorro S
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):5-16. PubMed ID: 26048031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
    Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
    Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
    Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
    Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors.
    Pinheiro C; Granja S; Longatto-Filho A; Faria AM; Fragoso MC; Lovisolo SM; Lerário AM; Almeida MQ; Baltazar F; Zerbini MC
    Oncotarget; 2015 Dec; 6(42):44403-21. PubMed ID: 26587828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.